← Back to Search

Mesenchymal Stem Cell Therapy

Cellgram™ (Bone marrow-derived MSCs) for Liver Cirrhosis

Phase 1
Waitlist Available
Led By Juan Gallegos-Orozco, Ph.D
Research Sponsored by Pharmicell Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This study is evaluating whether a single injection of stem cells can help improve liver function in individuals with alcoholic liver cirrhosis.

Eligible Conditions
  • Liver Cirrhosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Serious Adverse Events
Secondary outcome measures
Chronic liver disease as assessed by the Child-Pugh score
How well the Liver is functioning
Incidence of Adverse Events
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cellgram™ (Bone marrow-derived MSCs)Experimental Treatment1 Intervention
Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10^7 cells/10 mL (range: 4.5 x 10^7 to 5.5 x 10^7 cells/10 mL) via the hepatic artery.

Find a Location

Who is running the clinical trial?

Pharmicell Co., Ltd.Lead Sponsor
16 Previous Clinical Trials
730 Total Patients Enrolled
4 Trials studying Liver Cirrhosis
420 Patients Enrolled for Liver Cirrhosis
Juan Gallegos-Orozco, Ph.DPrincipal InvestigatorUniversity of Utah

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC
2019. "Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03838250.
All > Scs
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top